
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
over 29 years ago
The Three Dimensions of Managed Care Pharmacy Practiceover 29 years ago
Hospitals and Managed Care: Catching Up with the Networks





